Jazz Pharmaceuticals reports Q1 adjusted EPS $6.34, consensus $4.66

GAAP EPS was $4.43. Reports Q1 revenue $1.07B, consensus $979.01M. “Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026,” said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals (JAZZ). “Demand for Xywav remained strong, our rare oncology launches with Modeyso and Zepzelca in 1LM ES-SCLC gained significant momentum, and Epidiolex continued to provide consistent growth. Looking ahead, we are excited about the potential launch of zanidatamab in 1L GEA later this year, as we progress our pipeline and business development efforts to bring more life-changing therapies to patients and fuel durable long-term growth.”